1. Phylogeny  
TRIB1 is phylogenetically classified as a member of the Tribbles family of pseudokinases, which also includes TRIB2 and TRIB3. This family originates from the Drosophila tribbles gene and has been conserved throughout metazoan evolution, with orthologs present across vertebrates and particularly in mammals. Comparative sequence analysis demonstrates that TRIB1 shares significant sequence similarity with other family members, thereby grouping it with pseudokinases that display a kinase‐like domain yet lack key catalytic residues. Its evolutionary conservation underscores its fundamental regulatory role in cellular signaling despite its loss of canonical kinase catalytic function (danger2022thepseudokinasetrib1 pages 1-2, dobens2021controlofcell pages 2-4).

2. Reaction Catalyzed  
Unlike active serine/threonine kinases that catalyze the transfer of a phosphate group from ATP to protein substrates, TRIB1 does not catalyze a chemical reaction. Instead, it functions as an adaptor or scaffold protein that lacks reliable phosphotransferase activity. Therefore, no reaction of the form “ATP + protein → ADP + phosphorylated protein + H⁺” is carried out by TRIB1 (danger2022thepseudokinasetrib1 pages 2-4).

3. Cofactor Requirements  
Because TRIB1 is a pseudokinase that lacks enzymatic catalytic activity, its function does not depend on standard kinase cofactors such as Mg²⁺ or Mn²⁺. In canonical kinase reactions these ions are essential for ATP binding and phosphotransfer; however, the structural deviations in TRIB1’s pseudokinase domain obviate the need for such cofactors (danger2022thepseudokinasetrib1 pages 2-4).

4. Substrate Specificity  
TRIB1 selectively binds to protein substrates rather than catalyzing their phosphorylation. Its substrate specificity is primarily defined by its ability to recognize a conserved degron sequence within members of the CCAAT/enhancer-binding protein (C/EBP) family, notably C/EBPα. The recognition process involves direct binding of TRIB1 to the degron motif in C/EBPα, thereby targeting it for ubiquitin-mediated degradation in a COP1-dependent manner. Structural studies have identified that specific residues within the pseudokinase domain of TRIB1 are required to engage this recognition motif, establishing its substrate specificity as a determinant for modulating transcription factor stability (jamieson2018substratebindingallosterically pages 1-2, danger2022thepseudokinasetrib1 pages 7-9).

5. Structure  
TRIB1 is organized into three main regions. The N-terminal portion contains PEST sequences that are thought to dictate protein turnover and may contribute to subcellular localization signals. The central region exhibits a kinase-like or pseudokinase domain that retains the overall bilobal architecture characteristic of serine/threonine kinases; however, critical catalytic motifs such as the DFG motif are replaced by noncanonical sequences (e.g., an SLE motif), and key catalytic residues are missing. Consequently, the pseudokinase domain of TRIB1 is structurally intact and capable of binding ATP weakly (if at all), but it does not support phosphotransfer activity. The C-terminal tail of TRIB1 harbors a conserved COP1-binding motif that is essential for its adaptor function. In the absence of substrate, autoinhibitory intramolecular interactions between the kinase-like domain and the C-terminal tail mask this COP1-binding region. Crystallographic and molecular dynamics studies – particularly those elucidating the TRIB1–C/EBPα degron complex – have shown that binding of a substrate such as C/EBPα triggers conformational changes. These include re‐orientation of the activation loop and a shift of the αC-helix. The resulting “SLE-in” conformation relieves autoinhibition by displacing the C-terminal COP1-binding motif, thereby making it accessible for interaction with the E3 ubiquitin ligase COP1. This structural mechanism is central to TRIB1’s regulatory role in controlling substrate degradation (danger2022thepseudokinasetrib1 pages 2-4, jamieson2018substratebindingallosterically pages 1-2, jamieson2018substratebindingallosterically pages 5-6).

6. Regulation  
TRIB1 is regulated at both transcriptional and post-translational levels. Its mRNA and protein levels are tightly controlled, with rapid turnover attributed in part to the presence of PEST sequences in its N-terminal region. Post-translational regulation includes proteasome-dependent degradation, which is influenced by autoinhibitory interactions and by the binding of substrate. In its autoinhibited state, the C-terminal COP1-binding motif is sequestered by an intramolecular interaction with the pseudokinase domain. Binding of a substrate, such as C/EBPα, induces conformational changes that displace the COP1-binding motif, thereby relieving autoinhibition and permitting interaction with COP1. This process is further modulated by post-translational modifications; although specific phosphorylation events on TRIB1 have not been fully detailed, its regulation is influenced by downstream MAPK pathways and by signals that modulate its stability. Transcription factors, including FOXP3 (in regulatory T cells) and cMYC, have been implicated in modulating TRIB1 expression. In addition, microRNAs targeting the TRIB1 3′ UTR contribute to its post-transcriptional control. Together, these regulatory mechanisms ensure that TRIB1 functions as a molecular switch in response to specific cellular cues (danger2022thepseudokinasetrib1 pages 11-12, danger2022thepseudokinasetrib1 pages 15-16, iwamoto2015theroleof pages 1-2).

7. Function  
TRIB1 functions primarily as an adaptor protein that modulates protein degradation rather than as a catalytically active kinase. Its key biological role is to direct the activity of the COP1 ubiquitin ligase toward specific substrates such as C/EBPα. By binding selectively to the recognition sequence of C/EBPα, TRIB1 facilitates the ubiquitination and proteasomal degradation of this transcription factor, thereby modulating its intracellular levels. This regulatory event is critical for myeloid cell differentiation, as C/EBPα is a master regulator of hematopoiesis. Through this mechanism, TRIB1 influences the differentiation of macrophages, eosinophils, and neutrophils. In addition to its role in protein degradation, TRIB1 interacts with MAPK kinases and is involved in the regulation of MAP kinase signaling cascades. Although it lacks catalytic kinase activity, these interactions allow TRIB1 to modulate downstream signaling events that impact cell proliferation, differentiation, and survival. Expression data indicate that TRIB1 is present in a variety of tissues including hematopoietic cells, the liver, lung, and thyroid gland, which is consistent with its broad role in regulating both immune and nonimmune cell processes (danger2022thepseudokinasetrib1 pages 1-2, danger2022thepseudokinasetrib1 pages 15-16, jamieson2018substratebindingallosterically pages 2-3).

8. Other Comments  
No direct small-molecule inhibitors that target TRIB1 have been described; its pseudokinase nature precludes the use of classical kinase inhibitors that target ATP-binding sites. Instead, therapeutic strategies may focus on modulating its protein–protein interactions or its interactions with COP1. Disease associations for TRIB1 include its involvement in hematological malignancies such as acute myeloid leukemia, where mutations such as the R107L gain-of-function have been reported and linked to leukemogenesis. TRIB1 alterations are also observed in various solid tumors including prostate, colorectal, and lung cancers, and its dysregulation is linked to aberrant immune cell differentiation. In addition, TRIB1 is implicated by genome‐wide association studies in lipid metabolism and cardiovascular disease, particularly through regulatory effects in hepatic lipoprotein metabolism. Its role as an adaptor that modulates COP1 substrate specificity positions TRIB1 as a potential biomarker and therapeutic target in both oncogenic and metabolic disorders (danger2022thepseudokinasetrib1 pages 16-17, mayoralvaro2021thecriticalrole pages 13-15, douvris2014functionalanalysisof pages 29-33).

9. References  
1. Danger, R., Feseha, Y., & Brouard, S. (2022). The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. doi:10.3390/cancers14041011 (danger2022thepseudokinasetrib1 pages 1-2)  
2. Iwamoto, S., Boonvisut, S., Makishima, S., Ishizuka, Y., Watanabe, K., & Nakayama, K. (2015). The role of trib1 in lipid metabolism; from genetics to pathways. Biochemical Society transactions, 43(5), 1063-1068. doi:10.1042/bst20150094 (iwamoto2015theroleof pages 1-2)  
3. Hegedus, Z., Czibula, A., & Kiss-Toth, E. (2007). Tribbles: a family of kinase-like proteins with potent signalling regulatory function. Cellular Signalling, 19, 238-250. doi:10.1016/j.cellsig.2006.06.010 (hegedus2007tribblesafamily pages 9-11)  
4. Jamieson, S. A., Ruan, Z., Burgess, A. E., Curry, J. R., McMillan, H. D., Brewster, J. L., Dunbier, A. K., Axtman, A. D., Kannan, N., & Mace, P. D. (2018). Substrate binding allosterically relieves autoinhibition of the pseudokinase trib1. Science Signaling, Sep 2018. doi:10.1126/scisignal.aau0597 (jamieson2018substratebindingallosterically pages 1-2)  
5. Douvris, A., Soubeyrand, S., Naing, T., Martinuk, A., Nikpay, M., Williams, A., Buick, J., Yauk, C., & McPherson, R. (2014). Functional analysis of the trib1 associated locus linked to plasma triglycerides and coronary artery disease. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Jun 2014. doi:10.1161/jaha.114.000884 (douvris2014functionalanalysisof pages 29-33)  
6. Mayoral-Varo, V., Jiménez, L., & Link, W. (2021). The critical role of trib2 in cancer and therapy resistance. Cancers, 13, 2701, May 2021. doi:10.3390/cancers13112701 (mayoralvaro2021thecriticalrole pages 1-2)  
7. Nagiec, M. M., Skepner, A. P., Negri, J., Eichhorn, M., Kuperwasser, N., Comer, E., Muncipinto, G., Subramanian, A., Clish, C., Musunuru, K., Duvall, J. R., Foley, M., Perez, J. R., & Palmer, M. A. J. (2015). Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLOS ONE, 10, e0120295, Mar 2015. doi:10.1371/journal.pone.0120295 (nagiec2015modulatorsofhepatic pages 23-24)

References

1. (danger2022thepseudokinasetrib1 pages 1-2): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

2. (danger2022thepseudokinasetrib1 pages 16-17): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

3. (danger2022thepseudokinasetrib1 pages 2-4): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

4. (danger2022thepseudokinasetrib1 pages 7-9): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

5. (hegedus2007tribblesafamily pages 9-11): Z. Hegedus, A. Czibula, and E. Kiss-Toth. Tribbles: a family of kinase-like proteins with potent signalling regulatory function. Cellular Signalling, 19:238-250, Feb 2007. URL: https://doi.org/10.1016/j.cellsig.2006.06.010, doi:10.1016/j.cellsig.2006.06.010. This article has 178 citations and is from a peer-reviewed journal.

6. (iwamoto2015theroleof pages 1-2): S. Iwamoto, Supichaya Boonvisut, Saho Makishima, Y. Ishizuka, Kazuhisa Watanabe, and Kazuhiro Nakayama. The role of trib1 in lipid metabolism; from genetics to pathways. Biochemical Society transactions, 43 5:1063-8, Oct 2015. URL: https://doi.org/10.1042/bst20150094, doi:10.1042/bst20150094. This article has 30 citations and is from a peer-reviewed journal.

7. (jamieson2018substratebindingallosterically pages 1-2): Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, and Peter D. Mace. Substrate binding allosterically relieves autoinhibition of the pseudokinase trib1. Science Signaling, Sep 2018. URL: https://doi.org/10.1126/scisignal.aau0597, doi:10.1126/scisignal.aau0597. This article has 67 citations and is from a domain leading peer-reviewed journal.

8. (danger2022thepseudokinasetrib1 pages 11-12): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

9. (danger2022thepseudokinasetrib1 pages 15-16): R. Danger, Yodit Feseha, and S. Brouard. The pseudokinase trib1 in immune cells and associated disorders. Cancers, Feb 2022. URL: https://doi.org/10.3390/cancers14041011, doi:10.3390/cancers14041011. This article has 11 citations and is from a peer-reviewed journal.

10. (dobens2021controlofcell pages 2-4): LL Dobens and C Nauman. Control of cell growth and proliferation by the tribbles pseudokinase: lessons from drosophila. cancers 2021, 13, 883. Unknown journal, 2021.

11. (jamieson2018substratebindingallosterically pages 2-3): Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, and Peter D. Mace. Substrate binding allosterically relieves autoinhibition of the pseudokinase trib1. Science Signaling, Sep 2018. URL: https://doi.org/10.1126/scisignal.aau0597, doi:10.1126/scisignal.aau0597. This article has 67 citations and is from a domain leading peer-reviewed journal.

12. (jamieson2018substratebindingallosterically pages 5-6): Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, and Peter D. Mace. Substrate binding allosterically relieves autoinhibition of the pseudokinase trib1. Science Signaling, Sep 2018. URL: https://doi.org/10.1126/scisignal.aau0597, doi:10.1126/scisignal.aau0597. This article has 67 citations and is from a domain leading peer-reviewed journal.

13. (mayoralvaro2021thecriticalrole pages 1-2): Victor Mayoral-Varo, Lucía Jiménez, and Wolfgang Link. The critical role of trib2 in cancer and therapy resistance. Cancers, 13:2701, May 2021. URL: https://doi.org/10.3390/cancers13112701, doi:10.3390/cancers13112701. This article has 41 citations and is from a peer-reviewed journal.

14. (mayoralvaro2021thecriticalrole pages 13-15): Victor Mayoral-Varo, Lucía Jiménez, and Wolfgang Link. The critical role of trib2 in cancer and therapy resistance. Cancers, 13:2701, May 2021. URL: https://doi.org/10.3390/cancers13112701, doi:10.3390/cancers13112701. This article has 41 citations and is from a peer-reviewed journal.

15. (nagiec2015modulatorsofhepatic pages 23-24): Marek M. Nagiec, Adam P. Skepner, Joseph Negri, Michelle Eichhorn, Nicolas Kuperwasser, Eamon Comer, Giovanni Muncipinto, Aravind Subramanian, Clary Clish, Kiran Musunuru, Jeremy R. Duvall, Michael Foley, Jose R. Perez, and Michelle A. J. Palmer. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLOS ONE, 10:e0120295, Mar 2015. URL: https://doi.org/10.1371/journal.pone.0120295, doi:10.1371/journal.pone.0120295. This article has 34 citations and is from a peer-reviewed journal.

16. (douvris2014functionalanalysisof pages 29-33): Adrianna Douvris, Sébastien Soubeyrand, Thet Naing, Amy Martinuk, Majid Nikpay, Andrew Williams, Julie Buick, Carole Yauk, and Ruth McPherson. Functional analysis of the trib1 associated locus linked to plasma triglycerides and coronary artery disease. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Jun 2014. URL: https://doi.org/10.1161/jaha.114.000884, doi:10.1161/jaha.114.000884. This article has 61 citations and is from a domain leading peer-reviewed journal.